Natreon’s cardiovascular health ingredient Crominex 3+ granted US patent

The composition, now protected by patent number US10183047B2​​, was developed for its synergistic effect in improving the body’s lipid profile and endothelial function, according to the company.

“We are glad that USPTO has granted a well-deserved patent for cardiovascular health benefits of Crominex 3+, the most efficacious of several chromium supplements from the market,” ​said Dr Sanni Raju, CEO of Natreon.

“Crominex 3+ has amazing synergistic activity that showed significant improvement in endothelial function, lipid profile, hsCRP, as well as HbA1c, which are all important factors for cardiovascular health. Synergistic activity of Crominex 3+ is achieved by using totally natural materials.”​

There is currently one published study listed on PubMed, the clinical trials database managed by the US National Library of Medicine at the National Institutes of Health, that supports Crominex 3+’s endothelial function and lipid profile benefits.

The study, conducted by Italian researchers, found that Crominex 3+ was among the functional foods associated with a significant improvement of endothelial function with enhanced cholesterol lowering effects. It was published​​ in the journal BioMed Research International ​in January this year.

In a press release announcing the granted US patent, Natreon said that two clinical studies to be published soon show combining 10-20 mg of Crominex 3+ (200 mcg to 400 mcg of trivalent chromium) with 2 g of fish oil (600 mg of EPA + 400 mg of DHA) may enhance the health benefits of fish oil significantly.

“It is interesting to note that 10-20 mg of Crominex 3+ neither increases the size of the fish oil dosage form nor impacts the cost significantly, while enhancing fish oil’s numerous cardiovascular health benefits,”​ said Dr Raju.